Niarmedik
Russia
Central Federal District of the Russian Federation
Moscow
Aircraft designer Mikoyan, d. 12
Content |
Owners
NIARMEDIK is a Russian medical, innovative, biotechnological and pharmaceutical company. The main task of the office is to coordinate and manage the work of all clinics and warehouses included in the NIARMEDIK network.
NIARMEDIK PLUS Limited Liability Company is a Russian pharmaceutical, biotechnological, medical company established in 1989 by like-minded scientists of the N.F. Gamalei Research Institute of Epidemiology and Microbiology to introduce the results of their own scientific research and development in various fields of laboratory diagnostics, immunology, infectology and other areas into wide medical practice. The company produces diagnostic test systems, original pharmaceuticals, including the KAGOCEL antiviral drug and the COLLOST repair complex. It supplies to the domestic market laboratory equipment manufactured by leading world manufacturers, carries out its service services, and also develops a network of multidisciplinary clinics for the provision of comprehensive medical care. Today, NIARMEDIK PLUS is one of the TOP 10 best innovative companies in Russia that actively use biotechnology in medicine. CEO and founder of the company, Doctor of Medical Sciences, Professor Vladimir Nesterenko.
History
2021: JSC New Investment Holding bought Niarmedik for 5.9 billion rubles
On September 15, 2021, the sale of Niarmedik to AFK Sistema and Sberbank for 1 ruble was announced. The symbolic value of the transaction is due to the large debts of the pharmaceutical company - about 5.9 billion rubles.
Under the terms of the agreement, JSC New Investment Holding, owned by AFK Sistema and Sberbank, bought Nearmedic International Limited, which owns 100% of the authorized capital of Niarmedic Plus LLC, Niarmedic Pharma LLC and other companies operating in the fields of pharmaceuticals, biotechnology and medicine.
The agreement provides that AFK Sistema can buy a share of Sberbank and receive the rights to claim the bank's loan, which was provided to Niarmedik, in the amount of up to 2.8 billion rubles. The maximum term of execution of the agreement is 3.5 years from the closing date of the transaction.
President of AFK Sistema Vladimir Chirakhov, commenting on the deal, noted that Niarmedik has development potential that can be realized through restructuring and increasing efficiency.
 | It is in this that AFK Sistema, as an investment company, has a powerful and proven expertise. Moreover, AFK Sistema has accumulated significant competencies in pharmaceuticals, medicine and biotechnology - all these areas are key for Niarmedik, he said, adding that in the near future it is planned to implement a plan to optimize the business of Niarmedik, which is expected to increase the shareholder value of assets acquired under the transaction and expand the production capabilities of Sistema. |  |
By mid-September 2021, the Niarmedik group includes production sites in Obninsk and Mosalsk, a plant for the production of medical devices in Italy and a network of medical clinics in Moscow, Obninsk and Ryazan.[1]
2020
Association with the Center for Endosurgery and Lithotripsy
At the end of December 2020, it became known about the accession of the Center for Endosurgery and Lithotripsy (CELT) to the Niarmedik network of clinics, which, along with the Doctor Nearby network, is part of the united Doctor Nearby Holding LLC. The financial component of the transaction is not disclosed. More details here.
Creation of the company as a result of the merger of the Doctor Near and Niarmedik networks
In mid-July 2020, the Doctor Nearby and Niarmedick clinic networks completed the merger, which was announced a year earlier. According to the results of the transaction, the shares of the combined company - LLC United Company Niarmedik - Doctor Nearby - were distributed between the shareholders of Doctor Nearby and Niarmedik in relation to 45% to 55%, respectively. More details here.
2013
RUSNANO announced in December 2013 the successful withdrawal from the capital of NIARMEDIK PHARMA, a joint venture of RUSNANO and the Russian pharmaceutical company NIARMEDIK PLUS. The share of RUSNANO in the authorized capital of the project company - 34.45% - was bought for 2.3 billion rubles by the project applicant, NIARMEDIK PLUS LLC. The return on investments (IRR) of RUSNANO will be 41.1%.
RUSNANO's investments in the amount of 1.3 billion rubles were primarily directed to the construction of a company plant in the city of Obninsk, Kaluga Region. The total area of the complex, the commissioning of which in full is scheduled for 2014, will be 22 thousand square meters. The general contractor was FormaPharm Engineering Group, which has experience in designing and building more than a dozen modern pharmaceutical plants in Europe and Russia.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |